vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and APOGEE ENTERPRISES, INC. (APOG). Click either name above to swap in a different company.
APOGEE ENTERPRISES, INC. is the larger business by last-quarter revenue ($351.4M vs $247.1M, roughly 1.4× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 4.7%, a 6.4% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 1.6%). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 2.9%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Apogee Electronics is an American manufacturer of audio interfaces, analog-to-digital and digital-to-analog converters, USB & iOS microphones, and audio production software.
ANIP vs APOG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $351.4M |
| Net Profit | $27.5M | $16.6M |
| Gross Margin | — | 22.4% |
| Operating Margin | 14.1% | 7.3% |
| Net Margin | 11.1% | 4.7% |
| Revenue YoY | 29.6% | 1.6% |
| Net Profit YoY | 367.5% | 568.8% |
| EPS (diluted) | $1.14 | $0.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $351.4M | ||
| Q4 25 | $247.1M | $348.6M | ||
| Q3 25 | $227.8M | $358.2M | ||
| Q2 25 | $211.4M | $346.6M | ||
| Q1 25 | $197.1M | $345.7M | ||
| Q4 24 | $190.6M | $341.3M | ||
| Q3 24 | $148.3M | $342.4M | ||
| Q2 24 | $138.0M | $331.5M |
| Q1 26 | — | $16.6M | ||
| Q4 25 | $27.5M | $16.5M | ||
| Q3 25 | $26.6M | $23.6M | ||
| Q2 25 | $8.5M | $-2.7M | ||
| Q1 25 | $15.7M | $2.5M | ||
| Q4 24 | $-10.3M | $21.0M | ||
| Q3 24 | $-24.2M | $30.6M | ||
| Q2 24 | $-2.3M | $31.0M |
| Q1 26 | — | 22.4% | ||
| Q4 25 | — | 23.8% | ||
| Q3 25 | — | 23.1% | ||
| Q2 25 | — | 21.7% | ||
| Q1 25 | — | 21.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 28.4% | ||
| Q2 24 | — | 29.8% |
| Q1 26 | — | 7.3% | ||
| Q4 25 | 14.1% | 7.1% | ||
| Q3 25 | 15.9% | 7.5% | ||
| Q2 25 | 6.6% | 2.0% | ||
| Q1 25 | 13.3% | 1.8% | ||
| Q4 24 | -2.3% | 8.4% | ||
| Q3 24 | -13.8% | 12.3% | ||
| Q2 24 | 3.7% | 12.5% |
| Q1 26 | — | 4.7% | ||
| Q4 25 | 11.1% | 4.7% | ||
| Q3 25 | 11.7% | 6.6% | ||
| Q2 25 | 4.0% | -0.8% | ||
| Q1 25 | 8.0% | 0.7% | ||
| Q4 24 | -5.4% | 6.1% | ||
| Q3 24 | -16.3% | 8.9% | ||
| Q2 24 | -1.7% | 9.4% |
| Q1 26 | — | $0.78 | ||
| Q4 25 | $1.14 | $0.77 | ||
| Q3 25 | $1.13 | $1.10 | ||
| Q2 25 | $0.36 | $-0.13 | ||
| Q1 25 | $0.69 | $0.12 | ||
| Q4 24 | $-0.45 | $0.96 | ||
| Q3 24 | $-1.27 | $1.40 | ||
| Q2 24 | $-0.14 | $1.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $39.5M |
| Total DebtLower is stronger | — | $232.3M |
| Stockholders' EquityBook value | $540.7M | $511.8M |
| Total Assets | $1.4B | $1.1B |
| Debt / EquityLower = less leverage | — | 0.45× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $39.5M | ||
| Q4 25 | $285.6M | $41.3M | ||
| Q3 25 | $262.6M | $39.5M | ||
| Q2 25 | $217.8M | $32.8M | ||
| Q1 25 | $149.8M | $41.4M | ||
| Q4 24 | $144.9M | $43.9M | ||
| Q3 24 | $145.0M | $51.0M | ||
| Q2 24 | $240.1M | $30.4M |
| Q1 26 | — | $232.3M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $285.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $511.8M | ||
| Q4 25 | $540.7M | $512.3M | ||
| Q3 25 | $505.8M | $500.2M | ||
| Q2 25 | $436.8M | $481.8M | ||
| Q1 25 | $418.6M | $487.9M | ||
| Q4 24 | $403.7M | $522.1M | ||
| Q3 24 | $405.9M | $506.4M | ||
| Q2 24 | $455.8M | $480.0M |
| Q1 26 | — | $1.1B | ||
| Q4 25 | $1.4B | $1.1B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.3B | $1.2B | ||
| Q4 24 | $1.3B | $1.2B | ||
| Q3 24 | $1.3B | $917.1M | ||
| Q2 24 | $920.8M | $889.0M |
| Q1 26 | — | 0.45× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $122.5M |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | 7.8% |
| Cash ConversionOCF / Net Profit | 1.10× | 7.37× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $122.5M | ||
| Q4 25 | $30.4M | $29.3M | ||
| Q3 25 | $44.1M | $57.1M | ||
| Q2 25 | $75.8M | $-19.8M | ||
| Q1 25 | $35.0M | $30.0M | ||
| Q4 24 | $15.9M | $31.0M | ||
| Q3 24 | $12.5M | $58.7M | ||
| Q2 24 | $17.4M | $5.5M |
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $22.9M | ||
| Q3 25 | $38.0M | $52.4M | ||
| Q2 25 | $71.8M | $-26.9M | ||
| Q1 25 | $32.5M | $19.1M | ||
| Q4 24 | $13.5M | $22.0M | ||
| Q3 24 | $7.7M | $50.2M | ||
| Q2 24 | $13.0M | $-1.8M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 6.6% | ||
| Q3 25 | 16.7% | 14.6% | ||
| Q2 25 | 34.0% | -7.8% | ||
| Q1 25 | 16.5% | 5.5% | ||
| Q4 24 | 7.1% | 6.4% | ||
| Q3 24 | 5.2% | 14.7% | ||
| Q2 24 | 9.4% | -0.5% |
| Q1 26 | — | 7.8% | ||
| Q4 25 | 0.5% | 1.9% | ||
| Q3 25 | 2.7% | 1.3% | ||
| Q2 25 | 1.9% | 2.1% | ||
| Q1 25 | 1.3% | 3.2% | ||
| Q4 24 | 1.3% | 2.6% | ||
| Q3 24 | 3.2% | 2.5% | ||
| Q2 24 | 3.2% | 2.2% |
| Q1 26 | — | 7.37× | ||
| Q4 25 | 1.10× | 1.77× | ||
| Q3 25 | 1.66× | 2.41× | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | 12.08× | ||
| Q4 24 | — | 1.48× | ||
| Q3 24 | — | 1.92× | ||
| Q2 24 | — | 0.18× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
APOG
| Architectural Services | $127.1M | 36% |
| Architectural Metals | $110.0M | 31% |
| Architectural Glass | $67.4M | 19% |
| Performance Surfaces | $54.3M | 15% |
